Cargando…
A phosphorylation switch controls androgen biosynthesis in prostate cancer
Androgen biosynthesis enzyme 3β-hydroxysteroid dehydrogenase type 1 (3βHSD1) encoded by HSD3B1 has emerged as a potential driver for therapeutic resistance in prostate cancer. Patients with homozygous HSD3B1(1245C) inheritance are intrinsically more resistant to currently available androgen/androgen...
Autor principal: | Qiu, Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843042/ https://www.ncbi.nlm.nih.gov/pubmed/36647834 http://dx.doi.org/10.1172/JCI166499 |
Ejemplares similares
-
Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
por: Peinetti, Nahuel, et al.
Publicado: (2022) -
Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
por: Pechlivanis, Maree, et al.
Publicado: (2021) -
Statins and adrenal androgen levels in prostate cancer: A new twist
por: Mostaghel, Elahe A
Publicado: (2021) -
Protein translation controlled by the androgen receptor in prostate cancer: a novel therapeutic option?
por: Mirzakhani, Kimia, et al.
Publicado: (2020) -
Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)